NervGen Pharma Price To Book vs. Cash Flow From Operations

NGENF Stock  USD 1.87  0.05  2.60%   
Based on the key profitability measurements obtained from NervGen Pharma's financial statements, NervGen Pharma Corp may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in December. Profitability indicators assess NervGen Pharma's ability to earn profits and add value for shareholders.
For NervGen Pharma profitability analysis, we use financial ratios and fundamental drivers that measure the ability of NervGen Pharma to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well NervGen Pharma Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between NervGen Pharma's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of NervGen Pharma Corp over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
Please note, there is a significant difference between NervGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if NervGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NervGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

NervGen Pharma Corp Cash Flow From Operations vs. Price To Book Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining NervGen Pharma's current stock value. Our valuation model uses many indicators to compare NervGen Pharma value to that of its competitors to determine the firm's financial worth.
NervGen Pharma Corp is considered to be number one stock in price to book category among its peers. It also is considered to be number one stock in cash flow from operations category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NervGen Pharma's earnings, one of the primary drivers of an investment's value.

NervGen Cash Flow From Operations vs. Price To Book

Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

NervGen Pharma

P/B

 = 

MV Per Share

BV Per Share

 = 
5.13 X
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.

NervGen Pharma

Operating Cash Flow

 = 

EBITDA

-

Taxes

 = 
(8.27 M)
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.

NervGen Cash Flow From Operations Comparison

NervGen Pharma is currently under evaluation in cash flow from operations category among its peers.

NervGen Pharma Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in NervGen Pharma, profitability is also one of the essential criteria for including it into their portfolios because, without profit, NervGen Pharma will eventually generate negative long term returns. The profitability progress is the general direction of NervGen Pharma's change in net profit over the period of time. It can combine multiple indicators of NervGen Pharma, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. NervGen Pharma Corp. was incorporated in 2017 and is based in Vancouver, Canada. NERVGEN PHARMA operates under Biotechnology classification in the United States and is traded on OTC Exchange.

NervGen Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on NervGen Pharma. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of NervGen Pharma position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the NervGen Pharma's important profitability drivers and their relationship over time.

Use NervGen Pharma in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NervGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NervGen Pharma will appreciate offsetting losses from the drop in the long position's value.

NervGen Pharma Pair Trading

NervGen Pharma Corp Pair Trading Analysis

The ability to find closely correlated positions to NervGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NervGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NervGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NervGen Pharma Corp to buy it.
The correlation of NervGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NervGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NervGen Pharma Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NervGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your NervGen Pharma position

In addition to having NervGen Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Penny Thematic Idea Now

Penny
Penny Theme
Solid stocks, funds or ETFs with below average market capitalization and typicl daily price below 2. The Penny theme has 56 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Penny Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in NervGen OTC Stock

To fully project NervGen Pharma's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of NervGen Pharma Corp at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include NervGen Pharma's income statement, its balance sheet, and the statement of cash flows.
Potential NervGen Pharma investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although NervGen Pharma investors may work on each financial statement separately, they are all related. The changes in NervGen Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on NervGen Pharma's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.